In this Jan. 27, 2016, file photo, an Aedes aegypti mosquito known to carry the Zika virus, is photographed through a microscope at the Fiocruz institute in Recife, Pernambuco state, Brazil. (AP Photo/Felipe Dana, File)
Genetically modified mosquitoes are being released in the Florida Keys in an effort to combat persistent insect-borne diseases such as Dengue fever and the Zika virus.
The Florida Keys Mosquito Control District and the Oxitec biotechnology company announced Thursday that release boxes, non-release boxes and netted quality control boxes are being placed this week in six locations: two on Cudjoe Key, one on Ramrod Key and three on Vaca Key.
Starting early next month, less than 12,000 mosquitoes are expected to emerge each week for approximately 12 weeks. Untreated comparison sites will be monitored with mosquito traps on Key Colony Beach, Little Torch Key and Summerland Key.
“We really started looking at this about a decade ago, because we were in the middle of a dengue fever outbreak here in the Florida Keys,” Florida Keys Mosquito Control District executive director Andrea Leal said during a video news conference. “So we’re just very excited to move forward with this partnership, working both with Oxitec and members of the community.”
Keys officials approved the pilot project last year involving the striped-legged Aedes aegypti mosquito, which is not native to Florida. The insect transmits several diseases to humans, particularly in the Keys island chain where dozens of cases of dengue fever were reported last year.
Oxitec’s non-biting male mosquitoes are expected to mate with the local biting female mosquitoes. The female offspring of these encounters cannot survive, controlling the Aedes aegypti population. The Aedes aegypti mosquito makes up about 4% of the mosquito population in the Keys but is responsible for virtually all mosquito-borne diseases transmitted to humans. This mosquitoes transmit dengue, Zika, yellow fever and other human diseases, and can transmit heartworm and other potentially deadly diseases to pets and other animals.
An earlier version of the genetically-modified mosquitoes was used in Brazil, but this is the first time they have been used in the United States.
“We’re an organization comprised of very passionate individuals working to develop solutions that can have a public health impact,” Oxitec CEO Grey Frandsen said. “We have people living in the Keys. We have spent a huge amount of time engaging with residents, with community leaders, with small businesses, and have seen the results of that.”
Some people worry about using genetically-modified organisms, or GMOs, that they believe could alter the planet’s natural balance. Barry Wray, director of the Florida Keys Environmental Coalition, has said that officials have no idea what the insects will do.
It’s also unclear whether the genetically-modified mosquitoes will be able to accomplish their intended task, said Max Moreno, an expert in mosquito-borne diseases at Indiana University who is not involved in the company or the pilot project. Moreno has said the lab-created males might have a difficult time competing with rivals that have gone through the natural selection process, in which only the fittest survive and mate.
The genetically-modified mosquitoes have been approved by the Environmental Protection Agency and the Florida Department of Agriculture and Consumer Services, officials said. It also has support from the U.S. Centers for Disease Control and Prevention. The project is being funded by Oxitec.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
